NCT04105881

Brief Summary

During pregnancy , the maternal immune system is always confronted with fetal alloantigens. the immunological mechanisms that prevent the rejection of the fetus are still not under understood.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2020

Shorter than P25 for all trials

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 25, 2019

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 26, 2019

Completed
5 months until next milestone

Study Start

First participant enrolled

February 10, 2020

Completed
29 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 10, 2020

Completed
5 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 15, 2020

Completed
Last Updated

September 26, 2019

Status Verified

September 1, 2019

Enrollment Period

29 days

First QC Date

September 25, 2019

Last Update Submit

September 25, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Changes in number of B regulatory cell in pregnant woman

    Immune system immunosuppressed to maintain fetus

    9 months

Study Arms (3)

Full term labor

Measured by flow cytometry and ELUSA

Dietary Supplement: Investigation

Preterm labor

Measured by flow cytometry and ELISA

Dietary Supplement: Investigation

Control

For comparison

Dietary Supplement: Investigation

Interventions

InvestigationDIETARY_SUPPLEMENT

Cross sectional intervention

ControlFull term laborPreterm labor

Eligibility Criteria

Age20 Years - 50 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsFemale Patient should be informed before sampling
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

Healthy term delivery women and preterm labor women

You may qualify if:

  • healthy female according to the required groups

You may not qualify if:

  • patient with infectious disease , tuberculosis ,tumor ,hematologic disease,metabolic bone disease or any other connective tissue diseases were excluded.
  • Patient with viral hepatitis.
  • serological evidence of HIV infection.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Assiut university

Asyut, Asyut Governorate, Egypt

Location

Assiut university

Asyut, Egypt

Location

Related Publications (2)

  • Zahran AM, Zharan KM, Hetta HF. Significant correlation between regulatory T cells and vitamin D status in term and preterm labor. J Reprod Immunol. 2018 Sep;129:15-22. doi: 10.1016/j.jri.2018.07.004. Epub 2018 Jul 18.

  • Lima J, Martins C, Leandro MJ, Nunes G, Sousa MJ, Branco JC, Borrego LM. Characterization of B cells in healthy pregnant women from late pregnancy to post-partum: a prospective observational study. BMC Pregnancy Childbirth. 2016 Jun 6;16(1):139. doi: 10.1186/s12884-016-0927-7.

Biospecimen

Retention: SAMPLES WITH DNA

Total blood and serum

MeSH Terms

Conditions

Obstetric Labor, Premature

Interventions

Contact Tracing

Condition Hierarchy (Ancestors)

Obstetric Labor ComplicationsPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Intervention Hierarchy (Ancestors)

Epidemiologic MethodsInvestigative TechniquesPublic HealthEnvironment and Public HealthCommunicable Disease ControlPublic Health Practice

Study Officials

  • khalid Hassanein

    Microbiology and immunology department

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Khalid Hassanein, Professor

CONTACT

Helal Hetta, Lecturer

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principle investigator

Study Record Dates

First Submitted

September 25, 2019

First Posted

September 26, 2019

Study Start

February 10, 2020

Primary Completion

March 10, 2020

Study Completion

March 15, 2020

Last Updated

September 26, 2019

Record last verified: 2019-09

Locations